Related Experiment Video
Updated: Aug 24, 2025
12:24
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.3K
Microcystin-LR in Primary Liver Cancers: An Overview
Shen Gu1,2, Mingxuemei Jiang3, Bo Zhang1,2
1Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Toxins
|October 26, 2022
Summary
Microcystins (MCs), potent cyanobacterial toxins, are linked to liver cancer. This review details how MC-LR, a common MC variant, contributes to primary liver cancer (PLC) development and progression.
Area of Science:
- Environmental Science
- Toxicology
- Hepatology
Background:
- Cyanobacterial blooms in eutrophic waters are a global environmental concern.
- Microcystins (MCs), particularly MC-LR, are prevalent freshwater toxins released upon cell lysis or algaecide treatment.
- MC-LR is known for its severe hepatotoxicity and has been implicated in primary liver cancer (PLC) since 1992.
Purpose of the Study:
- To review and synthesize recent findings on MC-LR's role in primary liver cancer.
- To elucidate the mechanisms by which MC-LR induces or promotes PLC.
- To enhance understanding of MC-LR in PLC pathogenesis and guide future research.
Main Methods:
- Literature review of studies published over the past few years.
- Analysis of existing research on MC-LR toxicity and liver cancer.
- Synthesis of mechanistic insights into MC-LR's role in PLC.
Main Results:
- MC-LR plays a significant role in the initiation and progression of primary liver cancers.
- Multiple mechanisms contribute to MC-LR-induced hepatocarcinogenesis.
- Existing research highlights MC-LR's established link to liver cancer development.
Conclusions:
- MC-LR is a critical factor in primary liver cancer.
- Further research is needed to fully understand MC-LR's mechanisms in PLC.
- This review provides a foundation for future therapeutic and preventative strategies against MC-LR-related liver cancer.
